| Metric | Value (₹ Cr) | Q2 FY26 | Q3 FY25 |
|---|---|---|---|
| Revenue | 751.26 | 8.9% | 4.5% |
| Total Income | 760.21 | 9.3% | 5.7% |
| Expenditure | 734.53 | 14.8% | 0.9% |
| PBT | 25.68 | 209.7% | 353.3% |
| Net Profit | 16.90 | 205.7% | 346.4% |
| OPM | 5.68% | 6.66pp | 10.59pp |
| NPM | 2.22% | 4.13pp | 3.17pp |
| EPS | 2.56 | 6.2% | 348.5% |
Dhampur Bio Organics Approves Q3 Results and Explores Mycoprotein Production Opportunity with Planetary SA
21 Jan 2026 · 21 Jan, 9:53 pm
Summary
The Board of Directors at Dhampur Bio Organics has approved the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The company has also signed a non-binding term sheet with Planetary SA, Switzerland to explore the opportunity of exclusive production and commercialization of Mycoprotein in India.
Key Highlights
- 1
Unaudited (Standalone and Consolidated) Financial Results for the quarter and nine months ended December 31, 2025 approved
- 2
Non-binding term sheet signed with Planetary SA, Switzerland to explore Mycoprotein production and commercialization in India
Informational and educational content only. Not investment advice.